RESEARCH OBJECTIVE: The goal of this study was to examine prescription fill patterns of lipid-lowering agents among Medicare/ Medicaid dual-eligible patients by ethnicity. DATA AND METHODS: Study data were obtained from the Thomson Medstat MarketScan Medicaid claims database. Medicare/Medicaid beneficiaries who filled prescriptions for lipid-lowering agents during 2003 were included in the study. Logistic regression models estimated the probability that beneficiaries, by ethnicity, switched to a different lipid-lowering medication, augmented therapy with another lipid-lowering agent, or titrated the dosage of the drug upward over the course of the year. RESULTS: The models revealed that African Americans were less likely to switch lipid-lowering agents (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.60-0.78), augment lipid-lowering agents (OR, 0.53; 95% CI, 0.43-0.66), or titrate upward (OR, 0.75; 95% CI, 0.67-0.84) than whites. CONCLUSION: These results suggest that African Americans may be receiving less aggressive treatment than other patients, which in turn may explain why many studies find that African Americans are less likely to reach lipid goals. These treatment disparities merit further study, because they may impact dual-eligible patients moving into Medicare Part D plans.
RESEARCH OBJECTIVE: The goal of this study was to examine prescription fill patterns of lipid-lowering agents among Medicare/ Medicaid dual-eligible patients by ethnicity. DATA AND METHODS: Study data were obtained from the Thomson Medstat MarketScan Medicaid claims database. Medicare/Medicaid beneficiaries who filled prescriptions for lipid-lowering agents during 2003 were included in the study. Logistic regression models estimated the probability that beneficiaries, by ethnicity, switched to a different lipid-lowering medication, augmented therapy with another lipid-lowering agent, or titrated the dosage of the drug upward over the course of the year. RESULTS: The models revealed that African Americans were less likely to switch lipid-lowering agents (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.60-0.78), augment lipid-lowering agents (OR, 0.53; 95% CI, 0.43-0.66), or titrate upward (OR, 0.75; 95% CI, 0.67-0.84) than whites. CONCLUSION: These results suggest that African Americans may be receiving less aggressive treatment than other patients, which in turn may explain why many studies find that African Americans are less likely to reach lipid goals. These treatment disparities merit further study, because they may impact dual-eligible patients moving into Medicare Part D plans.
Authors: Ryan Mayhew; June M McKoy; Thanh Ha Luu; Isaac Lopez; Melissa Frick; Charles L Bennett Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981
Authors: Alyce S Adams; Jeanne M Madden; Fang Zhang; Stephen B Soumerai; Dan Gilden; Jennifer Griggs; Connie M Trinacty; Christine Bishop; Dennis Ross-Degnan Journal: Med Care Date: 2014-08 Impact factor: 2.983
Authors: Paula R Sherwood; Bassam A Dahman; Heidi S Donovan; Arlan Mintz; Charles W Given; Cathy J Bradley Journal: J Neurooncol Date: 2010-05-22 Impact factor: 4.130
Authors: Erik R Hoefgen; Annie L Andrews; Troy Richardson; Matthew Hall; John M Neff; Michelle L Macy; Jessica L Bettenhausen; Samir S Shah; Katherine A Auger Journal: Pediatrics Date: 2017-08-01 Impact factor: 7.124
Authors: Cecilia M Prela; Greg A Baumgardner; Gayle E Reiber; Lynne V McFarland; Charles Maynard; Nancy Anderson; Matthew Maciejewski Journal: Pharmacoeconomics Date: 2009 Impact factor: 4.981